About the Company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind ... - Nasdaq
C4 Therapeutics, Inc. (CCCC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue ... - Nasdaq
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.31 per share a year ago.
C4 Therapeutics, Inc. (CCCC)
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago. These ...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule ...
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
Sei Investments Co. Purchases New Shares in C4 Therapeutics, Inc ...
C4 Therapeutics, Inc. has a 1 year low of $1.09 and a 1 year high of $8.08. The company has a market cap of $88.03 million, a price-to-earnings ratio of -0.73 and a beta of 3.11.
C4 Therapeutics Announces Delivery of Second ... - Seeking Alpha
Forward-Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995.
Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now?
C4 Therapeutics, Inc. (NASDAQ:CCCC) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for CCCC is 66.
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.31 per share a year ago.
Similar Companies
Loading the latest forecasts...